Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen will virtually present at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 11:10 a.m. ET. Key executives, Murdo Gordon and Peter H. Griffith, will lead the presentation. Interested parties can access the conference via a live webcast on Amgen's website, which will also archive the event for 90 days. Amgen, a leading biotechnology company, focuses on innovative human therapeutics and has been recognized for its workplace and sustainability efforts.
Amgen's Board of Directors has declared a $1.94 per share dividend for the second quarter of 2022. This dividend will be paid on June 8, 2022, to stockholders of record by the close of business on May 17, 2022. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics aimed at serious illnesses. The company is recognized for its commitment to sustainability and workplace excellence, being listed among the 25 World's Best Workplaces™ and 100 most sustainable companies globally.
Amgen (NASDAQ:AMGN) announced positive outcomes from a pooled analysis of NAVIGATOR Phase 3 and PATHWAY Phase 2b trials, showcasing TEZSPIRE™ (tezepelumab-ekko) effectively reduced asthma exacerbation rates across various biomarker subgroups. The analysis revealed reductions of 71% in patients with high eosinophil counts, 48% in those with lower counts, and significant effectiveness across seasons, indicating TEZSPIRE's ability to manage severe asthma irrespective of inflammatory drivers. Approved in the U.S., TEZSPIRE is under review in the EU, Japan, and other markets.
Summary not available.
Summary not available.
Amgen (NASDAQ: AMGN) announced promising results from the CodeBreaK 100 trial for LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated advanced pancreatic cancer. The trial revealed a 21% objective response rate (ORR) and an 84% disease control rate (DCR) across 38 heavily pre-treated patients. The median progression-free survival was 4 months, and overall survival reached nearly 7 months. No new safety signals emerged, with treatment-related adverse events occurring in 42% of patients. Amgen plans to expand the trial to enroll more patients with various tumor types.
Amgen (NASDAQ:AMGN) outlines its growth strategy through 2030, focusing on expanding its global patient reach with innovative medicines. CEO Robert A. Bradway emphasizes a diverse portfolio in significant therapeutic categories, backed by a robust pipeline and strong balance sheet. CFO Peter Griffith projects mid-single digit revenue CAGR and approximately 50% operating margins. Key growth drivers include the launch of biosimilars and the anticipated success of therapies like Otezla and Repatha. Amgen aims to return an average of 60% of net income to shareholders, alongside significant capital investments.
On February 8, 2022, Amgen (NASDAQ: AMGN) provided long-term financial guidance for 2022-2030 during its virtual business review. The company expects to repurchase between $6 billion and $7 billion in shares, with $6 billion targeted for Q1 2022. GAAP diluted EPS guidance is projected between $13.08 and $14.13, while non-GAAP diluted EPS guidance ranges from $17.00 to $18.00. The business review is accessible via Amgen's investor relations website, with a comprehensive press release to follow, covering strategy and operations.
Amgen reported Q4 2021 total revenues of $6.8 billion, a 3% increase from Q4 2020, primarily due to increased other revenue from its COVID-19 collaboration with Lilly. For the full year, revenues rose 2% to $26.0 billion. GAAP EPS grew 22% to $3.36 in Q4 but dropped 16% to $10.28 for the year, mainly due to a $1.5 billion write-off from its acquisition of Five Prime Therapeutics. Non-GAAP EPS increased 26% in Q4 to $4.36 and 6% for the year to $17.10. Amgen generated $8.4 billion in free cash flow for 2021, a decrease from $9.9 billion in 2020. The company remains optimistic about long-term growth due to strong product volume growth.
Amgen (NASDAQ:AMGN) will host a virtual Business Review Meeting on Feb. 8, 2022, at 8:00 a.m. ET. CEO Robert A. Bradway and management will discuss the company's strategy, operations, pipeline, and growth outlook. The event will be broadcast online and is open to media, investors, and the public. The webcast will be archived for 90 days post-event. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics and has been recognized as one of the World's Best Workplaces and a top sustainable company.